Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:7083016.
doi: 10.1155/2017/7083016. Epub 2017 Jun 15.

Cardioprotection against Heart Failure by Shenfu Injection via TGF- β/Smads Signaling Pathway

Affiliations

Cardioprotection against Heart Failure by Shenfu Injection via TGF- β/Smads Signaling Pathway

Jingyu Ni et al. Evid Based Complement Alternat Med. 2017.

Abstract

Objective: To explore the potential cardioprotective mechanism of Shenfu injection (SFI) against heart failure (HF) by attenuating myocardial fibrosis and cardiac remodeling.

Methods and results: Four weeks after myocardial infarction (MI), adult male Sprague Dawley rats were randomized for 4-week treatment with Valsartan, SFI, or vehicle. Echocardiography and hemodynamics were applied to evaluate cardiac functions. Myocardia of coronary artery ligated (CAD) rats were observed to investigate changes in cardiac structure and function. Our findings suggest that treatment with SFI could inhibit progression of myocardial fibrosis and attenuate cardiac remodeling. In addition, SFI decreased expression of Smad2 and Smad3, while increasing the expression of Smad7 through regulation of TGF-β/Smads signaling pathway.

Conclusion: Treatment with SFI in Sprague Dawley rats improves ventricular structure and function and reduces cardiac fibrosis by ameliorating TGF-β/Smads signaling pathway after ventricular remodeling.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Echocardiographic characterization of cardiac systolic function in rats subjected to HF. Notes. Quantitative assessment of dilation and systolic function based on LVEF (a), LVFS (b), AV Peak V (c), LVIDs (d), LV systolic volume (LV Vols) (e), and LVPWs (f). Data are expressed as mean ± SD from ten animals. ∗∗P < 0.01 compared with the sham group; #P < 0.05 and ##P < 0.01 compared with the HF group.
Figure 2
Figure 2
Representative echocardiographic images (M-mode) in different groups. Notes. (a) Sham group, (b) HF group, (c) Valsartan + HF group, (d) SFI 1.5 mL/kg + HF group, and (e) SFI 0.75 mL/kg + HF group. HF, heart failure; SFI, Shenfu injection.
Figure 3
Figure 3
Representative transmitral valvular flow profiles and the color images acquired by color Doppler ultrasonography after 4-week drug administration, where the white shadow represents the aortic flow velocity. Notes. (a) Sham group, (b) HF group, (c) Valsartan + HF group, (d) SFI 1.5 mL/kg + HF group, and (e) SFI 0.75 mL/kg + HF group. HF, heart failure; SFI, Shenfu injection.
Figure 4
Figure 4
Hemodynamic assessment was performed to the left ventricle through right carotid artery to evaluate the role of SFI treatment in the management of HF. Notes. Quantitative assessment of hemodynamic on cardiac function based on HR (a), LVP (b), LVSP (c), LVEDP (d), +dp/dtmax (e), and −dp/dtmin (f). Data are expressed as mean ± SD from eight animals. ∗∗P < 0.01 compared with the sham group; #P < 0.05 and ##P < 0.01 compared with the HF group.
Figure 5
Figure 5
The experimental study of expression for Shenfu injection on myocardial miRNAs in rats with chronic congestive heart failure. (a) The intersection diagram of differentially expressed miRNA in three experiment groups. (b) Statistical analysis of seven miRNA expression differences in heart failure (n = 3). (c–e) GO analysis of differential genes. Notes. Compared with the sham group, ∗∗P < 0.01; compared with model group, #P < 0.05 and ##P < 0.01.
Figure 6
Figure 6
The effect of SFI on the content of NT-proBNP, TGF-β1, MMP-9, and CTGF of rat serum. Notes. Statistical results from ELISA for NT-proBNP (a), TGF-β1 (b), MMP-9 (c), and CTGF (d). Data are expressed as mean ± SD from ten animals. ∗∗P < 0.01 compared with the sham group; #P < 0.05 and ##P < 0.01 compared with the HF group. NT-proBNP, N-terminal probrain natriuretic peptide; TGF-β1, transforming growth factor-beta 1; MMP-9, matrix metalloproteinase-9; CTGF, connective tissue growth factor; SD, standard deviation; HF, heart failure; SFI, Shenfu injection.
Figure 7
Figure 7
The effect of SFI treatment on myocardial pathology in rats with HE staining after 4 weeks. Notes. (a) Sham group, (b) HF model group, (c) Valsartan + HF group, (d) SFI 1.5 mL/kg + HF group, and (e) SFI 0.75 mL/kg + HF group. Bar, 100 μm. HF, heart failure; SFI, Shenfu injection; HE, hematoxylin-eosin.
Figure 8
Figure 8
The effect of SFI treatment on left ventricular myocardial fibrosis in rats with Masson trichrome staining after 4 weeks. Notes. (a) Sham group, (b) HF model group, (c) Valsartan + HF group, (d) SFI 1.5 mL/kg + HF group, and (e) SFI 0.75 mL/kg + HF group. Myocardium was stained red and collagens were stained blue. Bar, 100 μm. HF, heart failure; SFI, Shenfu injection.
Figure 9
Figure 9
SFI regulates expression of TGF-β1, Smad2, Smad3, and Smad7 mRNA in rat hearts. Notes. The relative levels of cardiac TGF-β1 (a), Smad2 (b), Smad3 (c), and Smad7 (d) mRNA were assessed by real-time PCR. Results were normalized to GAPDH. Data are expressed as mean ± SD (each group, n = 3). ∗∗P < 0.01 compared with the sham group; #P < 0.05 and ##P < 0.01 compared with the HF model group. SFI, Shenfu injection; HF, heart failure; SD, standard deviation; PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGF-β1, transforming growth factor-beta 1.

References

    1. McMurray J. J. V., Adamopoulos S., Anker S. D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart Failure Association (HFA) of the esc. European Heart Journal. 2012;33(14):1787–1847. doi: 10.1093/eurheartj/ehs104. - DOI - PubMed
    1. Yancy W. C., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327. doi: 10.1161/CIR.0b013e31829e8776. - DOI - PubMed
    1. Gu D., Huang G., He J., et al. Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chinese Journal Cardiology. 2003;31(1):3–6.
    1. Radford M. J., Arnold J. M. O., Bennett S. J., et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards) Circulation. 2005;112(12):1888–1916. doi: 10.1161/CIRCULATIONAHA.105.170073. - DOI - PubMed
    1. Go A. S., Mozaffarian D., Roger V. L., et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292. - PMC - PubMed

LinkOut - more resources